PP52. ABERRATIONS IN TP53 AND P53 PATHWAY (MDM-2 AND P14ARF) GENES IN LOW GRADE GLIOMAS AND THEIR CLINICAL EFFECTS
EREN P.1, Uyar S.2, Topuzoğlu A.3, Kılıç T.4, Aker F.5, Erdağ B.6, Sav A.2, Pamir M.N.4, Çırakoğlu B1. 1. Marmara University Department of Medical Biology and Genetics; 2. Marmara University Institute of Neurological Sciences Department of Pathology, 3. Marmara University Department of Public Health, 4. Marmara University Department of Neurosurgery, 5. Haydarpasa Numune Research and Education Hospital Pathology Laboratuary; 6. Scientific and Technical Research Council of Turkey, Marmara Research Center e-mail: pinaren@yahoo.com; pinaren@gmail.com
*Corresponding Author:
page: 71

Abstract

Recently age and surgical resection of the tumor mass are the accepted variables important for glioma progression but the distinction of biological properties of glial tumours is extremely important for both the selection of the appropriate treatment method and the prolongation of the survival. Researches confirmed that p53 mutations are present in 60% of the initial stage gliomas and that 70-80 % of all gliomas had loss of p53 gene function. P14ARF and mdm2 aberrations effect P53 function and especially act on the progression through higher grade gliomas. In this study, tumour tissues of 39 and 9 patients applied to Marmara University Neurosurgery Department and Haydarpasa Numune Hospital respectively between April 1999- January 2005, accepted informed consent and had glioma surgery, are used; Following DNA isolation p53 mutations are detected by SSCP, mdm2 amplifications and P14 deletions are studied with multiplex PCR technique. Among Fourtyeight cases of this study 22 patients of the total group had p53 mutations. P53 protein expression of all three histopathological groups has found to be increased in mutation positive specimens than in non-mutated specimens at a statistically significant level (p<0.05). With the survival analysis p53 mutation carriers are found to live shorter compared to non-carriers. Patients with p53 mutations are considered to have unfavourable prognosis for this grade tumours. P14 deletions and MDM2 amplifications are not specific for this group of tumours and in this study they are not found to be statistically important.

Key Words; Low grade glioma, p53 mutations, p53 pathway aberrations, survival.




Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006